These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 24092908)

  • 1. Declining genital Warts in young women in england associated with HPV 16/18 vaccination: an ecological study.
    Howell-Jones R; Soldan K; Wetten S; Mesher D; Williams T; Gill ON; Hughes G
    J Infect Dis; 2013 Nov; 208(9):1397-403. PubMed ID: 24092908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decline in genital warts diagnoses among young women and young men since the introduction of the bivalent HPV (16/18) vaccination programme in England: an ecological analysis.
    Canvin M; Sinka K; Hughes G; Mesher D
    Sex Transm Infect; 2017 Mar; 93(2):125-128. PubMed ID: 27365492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Declines in anogenital warts diagnoses since the change in 2012 to use the quadrivalent HPV vaccine in England: data to end 2017.
    Checchi M; Mesher D; Mohammed H; Soldan K
    Sex Transm Infect; 2019 Aug; 95(5):368-373. PubMed ID: 30723186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation.
    Szarewski A; Skinner SR; Garland SM; Romanowski B; Schwarz TF; Apter D; Chow SN; Paavonen J; Del Rosario-Raymundo MR; Teixeira JC; De Carvalho NS; Castro-Sanchez M; Castellsagué X; Poppe WA; De Sutter P; Huh W; Chatterjee A; Tjalma WA; Ackerman RT; Martens M; Papp KA; Bajo-Arenas J; Harper DM; Torné A; David MP; Struyf F; Lehtinen M; Dubin G
    J Infect Dis; 2013 Nov; 208(9):1391-6. PubMed ID: 24092907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada.
    Kohli M; Lawrence D; Haig J; Anonychuk A; Demarteau N
    BMC Public Health; 2012 Oct; 12():872. PubMed ID: 23061913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human papillomavirus vaccination and genital warts in young Indigenous Australians: national sentinel surveillance data.
    Ali H; McManus H; O'Connor CC; Callander D; Kong M; Graham S; Saulo D; Fairley CK; Regan DG; Grulich A; Low N; Guy RJ; Donovan B
    Med J Aust; 2017 Mar; 206(5):204-209. PubMed ID: 28301790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors.
    Woestenberg PJ; King AJ; van der Sande MA; Donken R; Leussink S; van der Klis FR; Hoebe CJ; Bogaards JA; van Benthem BH; ;
    J Infect; 2017 Apr; 74(4):393-400. PubMed ID: 28126492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data.
    Donovan B; Franklin N; Guy R; Grulich AE; Regan DG; Ali H; Wand H; Fairley CK
    Lancet Infect Dis; 2011 Jan; 11(1):39-44. PubMed ID: 21067976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe.
    Marty R; Roze S; Bresse X; Largeron N; Smith-Palmer J
    BMC Cancer; 2013 Jan; 13():10. PubMed ID: 23298365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human papillomavirus vaccines effectiveness to prevent genital warts: A population-based study using health system integrated databases, 2009-2017.
    Muñoz-Quiles C; López-Lacort M; Díez-Domingo J; Rodrigo-Casares V; Orrico-Sánchez A
    Vaccine; 2022 Jan; 40(2):316-324. PubMed ID: 34865874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine.
    Garland SM; Steben M; Sings HL; James M; Lu S; Railkar R; Barr E; Haupt RM; Joura EA
    J Infect Dis; 2009 Mar; 199(6):805-14. PubMed ID: 19199546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of HPV vaccines against genital warts in women from Valencia, Spain.
    Navarro-Illana E; López-Lacort M; Navarro-Illana P; Vilata JJ; Diez-Domingo J
    Vaccine; 2017 Jun; 35(25):3342-3346. PubMed ID: 28499554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology of genital warts in the British population: implications for HPV vaccination programmes.
    Sonnenberg P; Tanton C; Mesher D; King E; Beddows S; Field N; Mercer CH; Soldan K; Johnson AM
    Sex Transm Infect; 2019 Aug; 95(5):386-390. PubMed ID: 30723185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genital warts and cost of care in England.
    Desai S; Wetten S; Woodhall SC; Peters L; Hughes G; Soldan K
    Sex Transm Infect; 2011 Oct; 87(6):464-8. PubMed ID: 21813567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England.
    Mesher D; Soldan K; Howell-Jones R; Panwar K; Manyenga P; Jit M; Beddows S; Gill ON
    Vaccine; 2013 Dec; 32(1):26-32. PubMed ID: 24211166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study.
    Leval A; Herweijer E; Ploner A; Eloranta S; Fridman Simard J; Dillner J; Young C; Netterlid E; Sparén P; Arnheim-Dahlström L
    J Natl Cancer Inst; 2013 Apr; 105(7):469-74. PubMed ID: 23486550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data.
    Ali H; Donovan B; Wand H; Read TR; Regan DG; Grulich AE; Fairley CK; Guy RJ
    BMJ; 2013 Apr; 346():f2032. PubMed ID: 23599298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significant decline of HPV 6 infection and genital warts despite low HPV vaccination coverage in young women in Germany: a long-term prospective, cohort data analysis.
    Denecke A; Iftner T; Iftner A; Riedle S; Ocak M; Luyten A; Üye I; Tunc K; Petry KU
    BMC Infect Dis; 2021 Jul; 21(1):634. PubMed ID: 34215215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability.
    Leval A; Herweijer E; Arnheim-Dahlström L; Walum H; Frans E; Sparén P; Simard JF
    J Infect Dis; 2012 Sep; 206(6):860-6. PubMed ID: 22815381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect on genital warts in Australian female and heterosexual male individuals after introduction of the national human papillomavirus gender-neutral vaccination programme: an analysis of national sentinel surveillance data from 2004-18.
    Chow EPF; Carter A; Vickers T; Fairley CK; McNulty A; Guy RJ; Regan DG; Grulich AE; Callander D; Khawar L; Machalek DA; Donovan B
    Lancet Infect Dis; 2021 Dec; 21(12):1747-1756. PubMed ID: 34339639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.